Difference between revisions of "Aminoglutethimide (Cytadren)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
'''This medication is no longer commercially available''' | '''This medication is no longer commercially available''' | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.<ref name="insert">[http:// | + | Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018202s021lbl.pdf Aminoglutethimide (Cytadren) package insert]</ref><ref>[[Media:Aminoglutethimide.pdf | Aminoglutethimide (Cytadren) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 8: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/aminoglutethimide.aspx Aminoglutethimide (Cytadren) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/aminoglutethimide.aspx Aminoglutethimide (Cytadren) patient drug information (Chemocare)]</ref> |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 02:49, 7 October 2012
This medication is no longer commercially available
General information
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]